FDA Is Still Lenient On COVID-19 EUAs, Veru’s Sabizabulin Advisory Panel Preview Docs Indicate

 
• By Sarah Karlin-Smith
arm curving into thumsb up
Agency still sees reasons to be flexible and grant EUAs for COVID-19 treatments, Veru’s adcomm preview documents indicate • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers